New Durvalumab Dosing Schedule Approved for Urothelial Carcinoma and Non-Small Cell Lung Cancer

 The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small cell lung cancer. "Durvalumab, a selective, high-affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, is approved in the US, Japan, and several other countries for the treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following conc...
Continue reading

Lenalidomide for High-Risk Smoldering Multiple Myeloma

​In results soon to be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), the E3A06 phase 3 clinical trial has found that single-agent lenalidomide (Revlimid®, Celgene) improves progression-free survival in patients with asymptomatic high-risk smoldering multiple myeloma (SMM). Smoldering multiple myeloma is a pre-cancerous, asymptomatic clonal plasma cell disorder with a high chance of progressing to multiple myeloma. Treatment for this condition has typically been li...
Continue reading

Killing Leukemia Cells by Disrupting Amino Acid Consumption

Researchers at Winship Cancer Institute of Emory University found that inhibiting amino acid metabolism hinders leukemia cell growth. The investigators report that ASCT2, a transporter enzyme that carries amino acids into cells, is a potential therapeutic target for cancer. "So far, little progress has been made in finding therapeutic targets in amino acid metabolic pathways that can be harnessed to kill cancer cells but spare normal cells," remarked Cheng-Kui Qu, MD, PhD, Professor in the Depar...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.